Enliven Therapeutics, Inc. (ELVN)
Develops cancer-fighting drugs targeting specific tumor-causing proteins.
$53.17+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+183.9%
The outlook
ELVN is trading near the top of its 52-week range, well above its key moving averages. All nine analysts covering the stock rate it a Strong Buy, with an average price target about 26% above the current price. The overall technical and sentiment setup appears decidedly bullish by recent standards.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range94% of the way from its 52-week low to high
Price targetAvg target +26% vs current price
Analyst price target
~12-month · 9 analysts$66.89average target+25.8% vs now
Now $53.17
Low $59.00High $80.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.80B
52-wk high
$55.79
52-wk low
$14.79
50-day avg
$45.51
200-day avg
$32.14
Trailing P/E
—